Charles Schwab
LOGC

Charles Schwab’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Charles Schwab’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,498
Closed -$27K – 3649
2021
Q4 		$27K Hold
11,498
– – ﹤0.01% 3563
2021
Q3 		$53K Buy
+11,498
New +$50.6K ﹤0.01% 3444
2021
Q2 		– Sell
-40,646
Closed -$296K – 3586
2021
Q1 		$296K Buy
40,646
+6,448
+19% +$53.1K ﹤0.01% 3250
2020
Q4 		$261K Buy
34,198
+8,278
+32% +$55.4K ﹤0.01% 3213
2020
Q3 		$236K Hold
25,920
– – ﹤0.01% 3128
2020
Q2 		$220K Buy
25,920
+7,751
+43% +$51K ﹤0.01% 3152
2020
Q1 		$90K Hold
18,169
– – ﹤0.01% 3115
2019
Q4 		$131K Hold
18,169
– – ﹤0.01% 3081
2019
Q3 		$197K Sell
18,169
-4,315
-19% -$46.2K ﹤0.01% 3039
2019
Q2 		$293K Buy
22,484
+1,969
+10% +$26.1K ﹤0.01% 3018
2019
Q1 		$203K Buy
20,515
+4,315
+27% +$40.2K ﹤0.01% 3020
2018
Q4 		$169K Buy
+16,200
New +$196K ﹤0.01% 3041

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Charles Schwab's LOGC Position: Q1 2022 in Review

Charles Schwab sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 11,498 shares — an estimated $27K sold.

Charles Schwab first reported a position in LOGC in Q4 2018 and held it in 12 quarters. The position peaked at $296K in Q1 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Charles Schwab reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 11,498 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $27K.
  • Charles Schwab first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 12 quarters.
  • Charles Schwab's LogicBio Therapeutics, Inc. Common Stock position peaked at $296K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.